Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.17 Consensus Price Target from Analysts

Context Therapeutics Inc. (NASDAQ:CNTX) has earned a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $6.1667.

A number of research firms recently weighed in on CNTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a research note on Friday, July 17th. Wall Street Zen lowered Context Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 20th. Citigroup reiterated an “outperform” rating on shares of Context Therapeutics in a report on Thursday. Finally, Maxim Group reduced their price target on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, June 16th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Virtu Financial LLC acquired a new stake in shares of Context Therapeutics in the 4th quarter worth about $43,000. Sanctuary Advisors LLC bought a new stake in Context Therapeutics during the 1st quarter worth approximately $51,000. Bank of New York Mellon Corp bought a new stake in Context Therapeutics during the 2nd quarter worth approximately $61,000. Quadrature Capital Ltd purchased a new stake in shares of Context Therapeutics in the fourth quarter worth approximately $68,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Context Therapeutics in the second quarter worth approximately $89,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Context Therapeutics Trading Down 27.3%

CNTX opened at $0.50 on Friday. The company has a fifty day moving average price of $0.91 and a two-hundred day moving average price of $1.92. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $3.62. The company has a market cap of $46.31 million, a P/E ratio of -1.05 and a beta of 1.74.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.06). On average, research analysts forecast that Context Therapeutics will post -0.39 EPS for the current fiscal year.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.